The Impact on Portal Hypertensive Gastropathy and Gastroesophageal Varices about Endoscopic Sclerotherapy and Ligation in the Treatment of Esophageal Varices

Objective: To explore the impact of portal hypertensive gastropathy and gastroesophageal varices about endoscopic sclerotherapy and ligation in the treatment of esophageal varices. Methods: 97 patients with bleeding after endoscopic treatment with liver cirrhosis upper gastrointestinal were chosen, among whom 19 cases were undergone endoscopic EVS treatment, 78 cases were undergone endoscopic treatment of EVL, 1 years of follow-up. 3 months, 6 months and 1 year later, the probability of occurring in patients with GV and PHG was observed. Results: After 3 months of treatment, the incidence of complications such as GV and PHG was17.5%(17/97) and 39.2%(38/97) respectively, compared with those before treatment, there was no significant difference(P0.05); After6 months of treatment, the incidence of complications was 32%(31/97) and 70.1%(68/97), compared with before treatment, there was a significant increase in the number(P0.05); After 1 year of treatment, GV, PHG rate was 42.3%(41/97) and 88.7%(86/97) respectively,concurrent number was significantly higher than that of before treatment(P0.05). Conclusion: Endoscopic EVS, EVL treatment can not only control esophageal varices bleeding, but also can increase the probability of concurrent PHG, GV, is worth the clinical prevention.